Effects of Video-Based Education on Symptom Management Self-Efficacy and Quality of Life in Women Receiving Chemotherapy for Breast Cancer
The Effect of a Video-Based Educational Intervention on Symptom Management Self-Efficacy and Quality of Life in Women With Breast Cancer Receiving Chemotherapy
This study is designed as a randomized controlled trial to evaluate the effect of a video-based educational intervention on symptom management self-efficacy and quality of life in women diagnosed with breast cancer who are receiving chemotherapy. The study will be conducted at the Day Chemotherapy Unit of Akdeniz University Hospital. The study sample will consist of female patients diagnosed with breast cancer who meet the inclusion criteria and consent to participate. Participants will be divided into two groups: an intervention group and a control group.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
This study is designed as a randomized controlled trial to evaluate the impact of a video-based educational intervention on self-efficacy for symptom management and quality of life in women diagnosed with breast cancer who are undergoing chemotherapy. The study will be conducted at the Day Chemotherapy Unit of Akdeniz University Hospital. The study sample will consist of women diagnosed with breast cancer who meet the inclusion criteria and consent to participate. Participants will be assigned to either an intervention group or a control group. The sample size was calculated using the G*Power 3.1.9 software, determining that a minimum of 72 participants-36 in each group-are required. Accounting for potential attrition, the study is planned to include a total of 90 participants, with 45 in the intervention group and 45 in the control group. In addition to routine care, patients in the intervention group will receive support for symptom management through a video-based educational intervention over a period of 8 weeks. Patients in the control group will receive the standard routine care provided at the study site. Data will be collected at three time points: baseline (T0), an interim follow-up (T1), and a final post-test (T2). The primary outcomes of the study are the level of self-efficacy regarding chemotherapy symptom management and quality of life. Secondary outcomes include the usability of the video-based educational intervention and instances of unplanned healthcare utilization (such as emergency department visits or unplanned hospital readmissions). Data collection will involve the use of a "Patient Information Form," the "Chemotherapy Symptom Management Self-Efficacy Scale for Breast Cancer," the "Functional Assessment of Cancer Therapy - Breast (FACT-B)," the "System Usability Scale," and a "Healthcare Utilization and Readmission Form" developed by the researcher. Data obtained from the study will be analyzed using the SPSS software package. It is anticipated that the video-based educational intervention will increase self-efficacy in symptom management among women diagnosed with breast cancer, improve their quality of life, and reduce the utilization of healthcare services, such as emergency department visits and hospital readmissions.
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Ümmühan Duman
- Numer telefonu: 02422450000/3314
- E-mail: ummuhan.duman@antalya.edu.tr
Lokalizacje studiów
-
-
Antalya
-
Antalya, Antalya, Turcja (Türkiye), 07190
- Antalya Bilim University
-
Kontakt:
- Ümmühan Duman
- Numer telefonu: 02422450000/3314
- E-mail: ummuhan.duman@antalya.edu.tr
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dziecko
- Dorosły
- Starszy dorosły
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Being 18 years of age or older,
- Being able to read and write in Turkish,
- Having no barriers to written or verbal communication,
- Being newly diagnosed with breast cancer and being aware of the diagnosis,
- Having received at least two cycles of chemotherapy,
- Having access to an internet-enabled digital device (e.g., smartphone), either personally owned or shared with family members, and being able to use it actively,
- Having an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.
Exclusion Criteria:
- Patients who do not agree to participate in the study,
- Patients participating in another study related to symptom management,
- Patients with a history of diagnosed psychiatric disorders,
- Patients with an Eastern Cooperative Oncology Group (ECOG) Performance Status of 3 or higher.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie podtrzymujące
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Podwójnie
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: INTERVENTION GROUP
In addition to routine care, patients in the intervention group will receive symptom management support over an 8-week period through a video-based educational intervention. |
Participants in the intervention group will receive an 8-week video-based educational intervention in addition to standard care. The web-based platform will provide evidence-based educational videos on chemotherapy-related symptoms and symptom management. Participants will be directed to symptom-specific videos through a rule-based algorithm based on their self-reported symptoms. They will be asked to access the platform at least three times per week and will receive reminder messages twice weekly. Platform usage will be monitored, and post-intervention assessments will be conducted after the 8-week intervention. |
|
Brak interwencji: CONTROL GROUP
Patients in the control group will receive the routine care provided at the center where the study is being conducted. |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Self-Efficacy Scale for Breast Cancer Related to Chemotherapy (SMSES-BC)
Ramy czasowe: Baseline (T0), Week 4 (T1), and Week 8 (T2).
|
Symptom management self-efficacy will be assessed using the Symptom Management Self-Efficacy Scale for Breast Cancer Related to Chemotherapy (SMSES-BC). Changes in self-efficacy scores will be evaluated across three assessment points. |
Baseline (T0), Week 4 (T1), and Week 8 (T2).
|
|
Functional Assessment of Cancer Therapy-Breast (FACT-B)
Ramy czasowe: Baseline (T0), Week 4 (T1), and Week 8 (T2).
|
Quality of life will be assessed using the Functional Assessment of Cancer Therapy-Breast (FACT-B). Changes in quality-of-life scores will be evaluated across three assessment points. |
Baseline (T0), Week 4 (T1), and Week 8 (T2).
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
System Usability Scale (SUS)
Ramy czasowe: At the end of the intervention (T2).
|
System usability will be assessed in the intervention group using the System Usability Scale (SUS) to evaluate participants' perceptions of the video-based educational platform. |
At the end of the intervention (T2).
|
|
Hospital Readmissions
Ramy czasowe: Week 8 (T2), covering the previous 8 weeks.
|
Hospital readmissions will be assessed using a researcher-developed healthcare utilization form, including the occurrence, frequency, and duration of hospital readmissions during the 8-week study period. |
Week 8 (T2), covering the previous 8 weeks.
|
|
Emergency Department Visits
Ramy czasowe: Week 8 (T2), covering the previous 8 weeks.
|
The number and reasons for emergency department visits during the 8-week study period will be assessed using a researcher-developed healthcare utilization form. |
Week 8 (T2), covering the previous 8 weeks.
|
|
Unplanned Healthcare Visits
Ramy czasowe: Week 8 (T2), covering the previous 8 weeks.
|
The frequency and reasons for unplanned outpatient clinic visits and other healthcare facility visits will be assessed using a researcher-developed healthcare utilization form. |
Week 8 (T2), covering the previous 8 weeks.
|
|
Treatment-Related Economic Burden
Ramy czasowe: Week 8 (T2), covering the previous 8 weeks.
|
Treatment-related economic burden will be assessed using a researcher-developed form to evaluate the financial burden associated with healthcare utilization during the study period. |
Week 8 (T2), covering the previous 8 weeks.
|
Współpracownicy i badacze
Sponsor
Sponsor
Śledczy
Śledczy
- Główny śledczy: Ümmühan Duman, Antalya Bilim University- ummuhan.duman@antalya.edu.tr
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- ABU_HEM_ÜD_2026
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .